Literature DB >> 3709615

The effect of bromocriptine on plasma catecholamine concentrations in normal volunteers.

L Steardo, E Di Stasio, S Bonuso, M Maj.   

Abstract

The effect of the ergot derivative bromocriptine (5 mg orally) on blood pressure and plasma catecholamine concentrations was explored in normal volunteers. A significant decrease of plasma noradrenaline was found, while dopamine and adrenaline concentrations did not change significantly. Systolic and diastolic blood pressures were significantly lowered at 150 min after administration. The hypotensive effect of bromocriptine seems to be mediated by a lowered release of noradrenaline from sympathetic nerve endings. It may be hypothesized that the drug stimulates presynaptic dopamine receptors located on postganglionic sympathetic nerves, thus inhibiting noradrenaline discharge.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709615     DOI: 10.1007/bf00615964

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  The cardiovascular effects of bromocriptine in Parkinsonism.

Authors:  J K Greenacre; P F Teychenne; A Petrie; D B Calne; P N Leigh; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  Bromocriptine blood-pressure lowering effect in migraine patients. A clinical investigation for a possible mechanism.

Authors:  L Steardo; E Marano; F Sorge
Journal:  Acta Neurol (Napoli)       Date:  1979-10

4.  Evidence for a peripheral dopaminergic mechanism in the antihypertensive action of lergotrile.

Authors:  A F Sved; J D Fernstrom
Journal:  Life Sci       Date:  1980-07-28       Impact factor: 5.037

5.  [Effects on arterial pressure of administration of a single dose (5 mg/per os) of bromocryptine].

Authors:  L Steardo; F Sorge; C Florio; E Marano; S Bonuso; G de Martino
Journal:  Acta Neurol Quad (Napoli)       Date:  1978

6.  Letter: Bromocriptine and hypertension.

Authors:  S B Kaye; K M Shaw; E J Ross
Journal:  Lancet       Date:  1976-05-29       Impact factor: 79.321

7.  Involvement of the adrenal glands in the hypotensive response to bromocriptine in spontaneously hypertensive rats.

Authors:  T C Hamilton
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

8.  Bromocriptine inhibits norepinephrine release.

Authors:  M G Ziegler; C R Lake; A C Williams; P F Teychenne; I Shoulson; O Steinsland
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

9.  Failure of bromocriptine to lower plasma catecholamines in normal men and women.

Authors:  D E Bybee; M Wiesen; N Aronin; D T Krieger; L A Frohman; I J Kopin
Journal:  J Clin Endocrinol Metab       Date:  1982-03       Impact factor: 5.958

10.  Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Identification of abnormal central dopamine control.

Authors:  K O Stumpe; R Kolloch; M Higuchi; F Krück; H Vetter
Journal:  Lancet       Date:  1977-07-30       Impact factor: 79.321

View more
  1 in total

1.  Enhancement of dopaminergic agonist bromocriptine of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.

Authors:  H Iishi; M Baba; M Tatsuta; S Okuda; H Taniguchi
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.